JPWO2020247419A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020247419A5
JPWO2020247419A5 JP2021571911A JP2021571911A JPWO2020247419A5 JP WO2020247419 A5 JPWO2020247419 A5 JP WO2020247419A5 JP 2021571911 A JP2021571911 A JP 2021571911A JP 2021571911 A JP2021571911 A JP 2021571911A JP WO2020247419 A5 JPWO2020247419 A5 JP WO2020247419A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
seq
bond
optionally
linkages
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021571911A
Other languages
English (en)
Japanese (ja)
Other versions
JP7795914B2 (ja
JP2022536085A5 (https=
JP2022536085A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/035811 external-priority patent/WO2020247419A2/en
Publication of JP2022536085A publication Critical patent/JP2022536085A/ja
Publication of JPWO2020247419A5 publication Critical patent/JPWO2020247419A5/ja
Publication of JP2022536085A5 publication Critical patent/JP2022536085A5/ja
Priority to JP2025133172A priority Critical patent/JP2026002847A/ja
Application granted granted Critical
Publication of JP7795914B2 publication Critical patent/JP7795914B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021571911A 2019-06-03 2020-06-03 神経学的疾患を処置するためのオリゴヌクレオチドおよびその使用方法 Active JP7795914B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025133172A JP2026002847A (ja) 2019-06-03 2025-08-08 神経学的疾患を処置するためのオリゴヌクレオチドおよびその使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962856264P 2019-06-03 2019-06-03
US62/856,264 2019-06-03
US201962914252P 2019-10-11 2019-10-11
US62/914,252 2019-10-11
US201962949817P 2019-12-18 2019-12-18
US62/949,817 2019-12-18
PCT/US2020/035811 WO2020247419A2 (en) 2019-06-03 2020-06-03 Oligonucleotides and methods of use for treating neurological diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025133172A Division JP2026002847A (ja) 2019-06-03 2025-08-08 神経学的疾患を処置するためのオリゴヌクレオチドおよびその使用方法

Publications (4)

Publication Number Publication Date
JP2022536085A JP2022536085A (ja) 2022-08-12
JPWO2020247419A5 true JPWO2020247419A5 (https=) 2023-06-06
JP2022536085A5 JP2022536085A5 (https=) 2023-06-06
JP7795914B2 JP7795914B2 (ja) 2026-01-08

Family

ID=73653367

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021571911A Active JP7795914B2 (ja) 2019-06-03 2020-06-03 神経学的疾患を処置するためのオリゴヌクレオチドおよびその使用方法
JP2025133172A Pending JP2026002847A (ja) 2019-06-03 2025-08-08 神経学的疾患を処置するためのオリゴヌクレオチドおよびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025133172A Pending JP2026002847A (ja) 2019-06-03 2025-08-08 神経学的疾患を処置するためのオリゴヌクレオチドおよびその使用方法

Country Status (12)

Country Link
US (1) US20220333105A1 (https=)
EP (1) EP3976010A4 (https=)
JP (2) JP7795914B2 (https=)
KR (1) KR20220033472A (https=)
CN (1) CN114555069A (https=)
AU (1) AU2020288555A1 (https=)
BR (1) BR112021024463A2 (https=)
CA (1) CA3142526A1 (https=)
IL (1) IL288574A (https=)
MX (1) MX2021014868A (https=)
PH (1) PH12021553024A1 (https=)
WO (1) WO2020247419A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020150290A2 (en) 2019-01-14 2020-07-23 President And Fellows Of Harvard College Methods and compositions for restoring stmn2 levels
EP4127172A4 (en) * 2020-03-25 2025-06-04 President and Fellows of Harvard College Methods and compositions for restoring STMN2 levels
EP4162051A4 (en) * 2020-06-03 2025-07-09 Quralis Corp TREATMENT OF NEUROLOGICAL DISEASES USING GENE TRANSCRIPT MODULATORS
WO2022018155A1 (en) * 2020-07-23 2022-01-27 F. Hoffmann-La Roche Ag Lna oligonucleotides for splice modulation of stmn2
WO2022018187A1 (en) * 2020-07-23 2022-01-27 F. Hoffmann-La Roche Ag Oligonucleotides targeting rna binding protein sites
AU2022255175A1 (en) * 2021-04-06 2023-11-23 Trace Neuroscience, Inc. Compositions and methods for treating tdp-43 proteinopathy
KR20240052763A (ko) * 2021-08-11 2024-04-23 아버 바이오테크놀로지스, 인크. 스타스민 2 (stmn2)를 표적화하는 rna 가이드를 포함하는 유전자 편집 시스템 및 이의 용도
AU2022402929A1 (en) * 2021-12-03 2024-06-13 Quralis Corporation Splice switcher antisense oligonucleotides with modified backbone chemistries
GB202208387D0 (en) * 2022-06-08 2022-07-20 Ucl Business Ltd Modified U7 snRNA construct
GB202208384D0 (en) * 2022-06-08 2022-07-20 Ucl Business Ltd Modified U7 snRNA construct
WO2024124203A2 (en) * 2022-12-09 2024-06-13 Auttx, Llc Targeted treatment of spliceopathy-induced neurological disorders
WO2024173645A1 (en) * 2023-02-15 2024-08-22 Arbor Biotechnologies, Inc. Gene editing method for inhibiting aberrant splicing in stathmin 2 (stmn2) transcript
WO2025184347A1 (en) * 2024-02-27 2025-09-04 Emory University Network analysis of the cerebrospinal fluid proteome of sporadic and familial forms of amyotrophic lateral sclerosis and methods of treatment of the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187545B1 (en) * 2000-01-19 2001-02-13 Isis Pharmaceuticals Inc. Antisense modulation of pepck-cytosolic expression
AU2002224787A1 (en) * 2000-10-23 2002-05-06 Mermaid Pharmaceuticals Gmbh Method for temporally controlling antisense-mediated gene inactivation
US20030104410A1 (en) * 2001-03-16 2003-06-05 Affymetrix, Inc. Human microarray
JP2007104971A (ja) * 2005-10-14 2007-04-26 New Industry Research Organization ミオスタチンのスプライシング制御アンチセンスオリゴヌクレオチド
EP1815863A1 (en) * 2006-02-03 2007-08-08 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Use of TLR3 agonists for the treatment of neurodegenerative disorders
US20110286997A1 (en) * 2007-03-13 2011-11-24 Hakon Hakonarson Genetic Alterations on Chromosome 16 and Methods of Use Thereof for the Diagnosis and Treatment of Type 1 Diabetes
CA2762987A1 (en) * 2009-05-22 2010-11-25 Joseph Collard Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
WO2012005898A2 (en) * 2010-06-15 2012-01-12 Alnylam Pharmaceuticals, Inc. Chinese hamster ovary (cho) cell transcriptome, corresponding sirnas and uses thereof
WO2012177639A2 (en) * 2011-06-22 2012-12-27 Alnylam Pharmaceuticals, Inc. Bioprocessing and bioproduction using avian cell lines
EP2788487B1 (en) * 2011-12-08 2018-04-04 Sarepta Therapeutics, Inc. Oligonucleotide analogues targeting human lmna
ES2807379T3 (es) * 2013-03-14 2021-02-22 Ionis Pharmaceuticals Inc Composiciones y métodos para regular la expresión de Tau
US20160235843A1 (en) * 2013-10-03 2016-08-18 The General Hospital Corporation Methods for increasing neuronal survival
WO2016060919A1 (en) * 2014-10-14 2016-04-21 The Board Of Regents Of The University Of Texas System Allele selective inhibition of mutant c9orf72 foci expression by duplex rnas targeting the expanded hexanucleotide repeat
WO2017079352A2 (en) * 2015-11-04 2017-05-11 Idera Pharmaceuticals, Inc. Compositions for inhibiting nlrp3 gene expression and uses thereof
CA3103429A1 (en) * 2018-06-14 2019-12-19 Don W. Cleveland Compounds and methods for increasing stmn2 expression
EP4127172A4 (en) * 2020-03-25 2025-06-04 President and Fellows of Harvard College Methods and compositions for restoring STMN2 levels

Similar Documents

Publication Publication Date Title
CN111373043B (zh) 用于降低snca表达的化合物和方法
JP2022536085A (ja) 神経学的疾患を処置するためのオリゴヌクレオチドおよびその使用方法
JPWO2020247419A5 (https=)
EP3765476B1 (en) Modified oligonucleotides for use in treatment of tauopathies
JP2015516953A (ja) 発作を減少させるためおよび神経変性症候群を改質するためにタウ発現を調節する方法
US20250051766A1 (en) Treatment of neurological diseases using modulators of unc13a gene transcripts
WO2023102242A9 (en) Splice switcher antisense oligonucleotides with modified backbone chemistries
IL313205A (en) Microbial consortia
US20230235332A1 (en) Treatment of neurological diseases using modulators of gene transcripts
WO2023102548A1 (en) Treatment of neurological diseases using modulators of kcnq2 gene transcripts
WO2023102188A1 (en) Gapmer antisense oligonucleotides with modified backbone chemistries
RU2021138237A (ru) Олигонуклеотиды и способы применения для лечения неврологических заболеваний
JPWO2023102225A5 (https=)
KR20230151507A (ko) 엑손-51의 스키핑을 통한 dmd 환자의 디스트로핀 구제를 위한 올리고머 화합물
JPWO2021247800A5 (https=)
JPWO2023102242A5 (https=)
HK40121031A (zh) 具有经修饰的主链化学的剪接转换器反义寡核苷酸
WO2023102227A2 (en) Treatment of neurological diseases using modulators of smn2 gene transcripts
IL313204A (en) Methods for the synthesis of factor D complement inhibitors
EP4720294A2 (en) Modified unc13a oligonucleotides
HK40121931A (zh) 具有修饰的主链化学的gapmer反义寡核苷酸
HK40097883A (zh) 使用基因转录物调控剂治疗神经学疾病